When Vanessa, a travel nurse from Memphis, Tennessee, received a stage 3 triple-negative breast cancer diagnosis, her meticulously planned future was abruptly halted. Even with her medical background, she found herself facing an unfamiliar and daunting reality. “I’ve taken care of patients my whole life,” she says, “but I didn’t really know what breast cancer truly entailed.” The diagnosis soon escalated to metastatic disease, a moment she describes as “an awful feeling to know you have to go through treatment again.”
Triple-negative breast cancer is known for its aggressive nature, growing and spreading more quickly than other types. For about half of women with metastatic triple-negative breast cancer, the first treatment may be the only chance to control the disease, making the initial choice of therapy crucial. This subtype also disproportionately affects younger women and has higher incidence rates in Black and Hispanic women, emphasizing the urgent need for accessible education and treatment options in these communities.
Historically, treatment options for metastatic triple-negative breast cancer were largely limited to chemotherapy, which impacts cancer cells more than normal cells. However, recent advancements have introduced antibody-drug conjugates (ADCs), a class of medicines designed to target specific markers on cancer cells and deliver treatment more directly. Until recently, ADCs were reserved for later stages of treatment, but now they can be considered as a first-line option for some patients.
Vanessa’s medical oncologist, Dr. Gregory Vidal, MD, PhD, Director of Clinical Research at West Cancer Center and Associate Professor at the University of Tennessee Health Science Center, emphasizes the importance of individualized care: “When selecting treatment, it’s important to consider patients’ goals, wishes and needs so that we can try to realistically plan around those. All patients are different and may qualify for different ADCs.” He encourages patients to engage in open dialogue with their care teams and ask about treatment goals appropriate for their stage.
For Vanessa, receiving an ADC as her first treatment has made a significant difference. It has allowed her to plan ahead, balancing good days and bad days, and to focus on what matters most: time with family and friends. While not all patients are eligible for ADCs, understanding when they might be considered and their potential impact on daily life can empower patients during discussions with their healthcare providers.
The emotional and physical toll of treatment has been challenging, but Vanessa has leaned on her support system to maintain a “faith over fear” mindset. She advises others living with metastatic breast cancer to “stay positive, ask questions and advocate for themselves during treatment conversations.” Her journey underscores the importance of being proactive and informed. “You definitely have a fight in front of you, but you can get through this. You have to do your research and get answers,” she says.
Innovations like ADCs are offering new hope for patients with metastatic triple-negative breast cancer, helping to keep the disease from growing and improving quality of life. For more insights into how patients are navigating ADC treatment, visit Expose-MBC.com/ADC.
